TikoMed logo

News & Events

We are proud of our achievements and want to share our successes. You can find the latest information on our projects, publications and events here.

Find what you are looking for:​
  • Search:

All News & Events

TikoMed announces the publication of results from an open-label, single arm, single center phase II trial carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics and Biomarkers (D3B) team in patients with confirmed Amyotrophic Lateral Sclerosis (ALS) treated with weekly ILB® injections.

The trial outcomes demonstrated that: TikoMed is now moving forward with planning a phase IIb multi-centre efficacy trial of ILB® Viken, Sweden July 22nd, 2024: Swedish drug development company TikoMed AB today announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran

22 July, 2024

The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have officially signed a research collaboration agreement.

Oslo, June 25th, 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have recently signed a research collaboration agreement. Common ambition for the parties is for their collaboration to lead to more knowledge and better treatment options for patients diagnosed with Amyotrophic

27 June, 2024

The Division of Clinical Neuroscience vid Oslo universitetssjukhus och det svenska biofarmabolaget TikoMed har officiellt undertecknat ett forskningssamarbetsavtal.

Oslo, 27 juni, 2024. The Division of Clinical Neuroscience vid Oslo universitetssjukhus och det svenska biofarmabolaget TikoMed har nyligen undertecknat ett forskningssamarbetsavtal. Parterna är överens om att samarbetet ska leda till mer kunskap och bättre behandlingsalternativ för patienter med diagnosen Amyotrofisk lateralskleros – ALS. TikoMed har tidigare genomfört och rapporterat

27 June, 2024

TikoMed will be at BIO Europe Spring 2024

Our CEO, Adam Bruce, will be attending BIO Europe Spring, March 18-20, Barcelona, Spain. Reach out to schedule a meeting and learn more about our groundbreaking drug candidate ILB®, targeted at improving outcomes for people suffering from otherwise untreatable progressive and disabling neurodegenerative diseases, including:  ✅ amyotrophic lateral sclerosis (ALS)✅

7 March, 2024
Claus Sundgreen

TikoMed Presenting at ALS ONE Annual Symposium

Claus Sundgreen, MD, TikoMed’s Consultant Medical Director, will be presenting at ALS ONE‘s annual Symposium. Don’t miss his highly interesting and informative talk titled: ILB®: A Novel Therapeutic Agent for ALS Targeting Excitotoxicity, Mitochondrial Dysfunction, and InflammationFriday, November 17th2:25-2:45pm EST #ALS#neurodegeneration

17 November, 2023